AstraZeneca reports strong third quarter
This article was originally published in Scrip
Executive Summary
AstraZeneca has reported a strong third quarter, with sales growth of 9% and net profits of $1.74 billion, a 29% leap. Core EPS, excluding restructuring and charges, rose by 27% to $1.32.